Oops, an error occurred! Code: 20190823194006a30aea4f

numares. |One Sample - All Answers.

3

Locations: Boston, MA;
Regensburg, GE; Singapore

60+

employees of medical and
scientific disciplines

2004

Founded as a spin-off of
Regensburg University

1.5M+

analyses worldwide with numares
technology


Mastering Metabolite Constellations. |For Precision Diagnostics.

numares is an innovative diagnostics company. We focus on the discovery, development and commercialization of diagnostic tests, using metabolite constellations to solve unmet medical needs that could not be addressed by single biomarker-based medicine.

 

Our diagnostic test are based on the interpretation of biomarker in the metabolism, whose dynamics and relation to each other allow for predicting disease progression. These metabolite constellations create diagnostics of a new generation: non-invasive, timely and meaningful at manageable costs.

Company Milestones

2019

numares announces collaboration with Mayo Clinic Laboratories on the development of new diagnostic tests

2018

numares completes another financing round

2018

Start of pan-European multicenter study PARASOL to evaluate metabolite constellations to detect kidney allograft rejection

2017

Launch of AXINON® renalTX-SCORE®-U100: first metabolomics IVD test for allograft rejection diagnostics after kidney transplantation

2017

Collaboration with Oxford University on the development of Multiple Sclerosis diagnostic test

2016

1,000.000 performed analyses

2016

numares completes another financing round

2015

Launch of CE-marked IVD test AXINON® lipoFIT®-S100 for comprehensive NMR-based lipoprotein profiling

2014

600.000 performed analyses

2014

Successful completion of studies on kidney transplantation

2014

Cooperation with a German laboratory network: commissioning of a test system for lipoprotein profiling

2013

200.000 performed analyses

2013

Bulk order from a U.S. laboratory chain: installation of multiple test systems for lipoprotein profiling

2013

Successful certification of numares according to EN ISO 13485: 2012 as a manufacturer of in-vitro diagnostics (IVD)

2010

100.000 performed analyses

2009

Certification as per EN ISO 13485:2003

As off 2005

Measurements within large studies such as GRAPHIC and KORA

2004

First patent for the determination of lipoproteins in body fluids (lipoprotein profiling)

Leadership

“We at numares are convinced that using A.I. and our proprietary methods to depict meaningful metabolite constellations will take patient health care and precision medicine to a new level.”

Dr. Volker Pfahlert

Chief Executive Officer & Chairman of the Executive Board at numares

 

“With software-based diagnostic tests for our modular AXINON® IVD System, we are focusing on improving patient care at affordable healthcare costs.”

Dr. Claus Botzler, MBA

Chief Operating Officer & Executive Board at numares

 

“The single biomarker-based medicine is at its limits. Exploiting the dynamics of metabolite biomarker constellations opens up undreamt-of possibilities to solve important medical questions.”

Dr. Philipp Pagel

Chief Medical Officer at numares 

 

“AXINON® combines flexibility, personalization and high-tech - ideal conditions to make diagnostics available for everyone, to minimize healthcare costs and maximize shareholder value.”

Florian Voss

Head of Finance & Administration at numares 

“Although our AXINON® IVD System requires only minimal operator interaction, it is our claim to accompany our clients with the best support – beyond set-up and maintenance.”

Dr. Lutz Niggl

Head of Service at numares 

 

“The combination of metabolomics and MGS® to develop new, meaningful diagnostic solutions holds great potential. It is my aim making numares' disruptive diagnostic technology available to US customers.”

Sean Keohane, MBA

Vice President US Marketing & Sales at numares